Publications by authors named "U A Patel"

Arylacetic acid equivalents bearing a pyridine group undergo C(sp)-H/C(sp)-H cross coupling with diverse methylarenes in the presence of a copper based catalyst system. The reaction proceeds the formation of α-carbonyl radicals giving access to α,β-diarylpropionic acids. Preliminary study suggests that the catalyst system is capable of transforming arylbenzyl ketones into 1,2,3-triaryl ketones.

View Article and Find Full Text PDF

Purpose Hepatic abscesses remain a significant clinical challenge due to high morbidity and mortality. This research aims to examine the etiological spectrum, management approaches, clinical features, and results in hepatic abscesses in a tertiary care facility in northern India, emphasizing the distinctions among pyogenic liver abscesses (PLAs) and amoebic liver abscesses (ALAs). Methods This retrospective study was done at GSVM Medical College, Kanpur, analyzing 725 patients with hepatic abscesses over a 10-year period.

View Article and Find Full Text PDF

High-energy nuclear collisions create a quark-gluon plasma, whose initial condition and subsequent expansion vary from event to event, impacting the distribution of the eventwise average transverse momentum [P([p_{T}])]. Disentangling the contributions from fluctuations in the nuclear overlap size (geometrical component) and other sources at a fixed size (intrinsic component) remains a challenge. This problem is addressed by measuring the mean, variance, and skewness of P([p_{T}]) in ^{208}Pb+^{208}Pb and ^{129}Xe+^{129}Xe collisions at sqrt[s_{NN}]=5.

View Article and Find Full Text PDF
Article Synopsis
  • Resmetirom is a newly FDA-approved drug for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition that can lead to cirrhosis and cancer.
  • It has been shown to significantly reduce liver fat, improve liver tissue health, and enhance metabolic health, leading to the resolution of non-alcoholic steatohepatitis (NASH) and fibrosis in many patients.
  • Although it may cause some gastrointestinal side effects, resmetirom is generally considered safe, and ongoing phase 3 trials will provide more information on its long-term effectiveness and safety.
View Article and Find Full Text PDF

Digital health platforms for asthma self-management have demonstrated promise in improving clinical and quality of life outcomes. However, few studies have examined such an approach in a real-world, fully remote setting. As such, we evaluated the benefit of an evidence-based digital self-management platform for asthma-both on its own and when integrated into an established virtual clinical service.

View Article and Find Full Text PDF